It has been observed that Aza mitigates GVHD in murine models by converting alloreactive CD4+CD25+FOXP3- cells to suppressive CD4+CD25+FOXP3+ Tregs and directly increase Treg proliferation. The gene discussed is FOXP3; the disease is graft versus host disease.